Sugi Predict

Sugi Predict / Compounds / SCHEMBL5149405

SCHEMBL5149405

SCHEMBL5149405

CC(C)(Cc1ccc(Br)cc1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BLM P54132 2/20 0.46
▸ MME P08473 2/20 0.44
▸ LMNA P02545 1/20 0.42
▸ PPARD Q03181 2/20 0.40
▸ PPARA Q07869 2/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ CYP4F2 P78329 1/20 0.39
▸ CYP4A11 Q02928 1/20 0.39
▸ CTSS P25774 1/20 0.39
▸ CTSK P43235 1/20 0.39
▸ FPR2 P25090 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ CTDSP1 Q9GZU7 1/20 0.39
▸ RXRA P19793 1/20 0.39
▸ RXRB P28702 1/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12492687 0.84 BLM (0.46) BLMMMELMNAPPARDPPARA
SCHEMBL10767808 0.84 LMNA (0.42) BLMMMELMNAMEN1KMT2A
SCHEMBL27925093 0.83 ESR1 (0.56) BLMLMNAPPARAMEN1KMT2A
SCHEMBL2175090 0.82 BLM (0.44) BLMMMELMNAPPARDPPARA
SCHEMBL2175094 0.82 BLM (0.44) BLMMMELMNAPPARDPPARA
SCHEMBL4457891 0.82 BLM (0.47) BLMPPARAKMT2AL3MBTL1KDM4E
SCHEMBL6668736 0.82 BLM (0.52) BLMLMNAMEN1KMT2ACYP4F2
SCHEMBL11596247 0.82 BLM (0.67) BLMMEN1KMT2ACYP4F2CYP4A11
SCHEMBL517462 0.81 SMN1; SMN2 (0.57) BLMLMNAPPARAALDH1A1CYP1A2
SCHEMBL12530276 0.81 BLM (0.71) BLMMMELMNAPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655382-B1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) 2022-09-28 — — EP disclosed
US-11261190-B2 Dihydropyrimidine compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-03-01 — — US disclosed
CN-109678859-B Dihydropyrimidine compound and application thereof in medicine 广东东阳光药业有限公司 2020-12-29 — — CN disclosed
US-20200283445-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-09-10 — — US disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 — — US disclosed
EP-1673336-B1 CATHEPSIN CYSTEINE PROTEASE INHIBITORS MERCK CANADA INC (CA) 2014-06-04 — — EP disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 — — US disclosed
EP-2655382-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME Ludwig-Maximilians-Universität München (DE) 2013-10-30 — — EP disclosed
WO-2012085168-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2012-06-28 — — WO disclosed
US-7312353-B2 Cathespin cysteine protease inhibitors MERCK FROST CANADA & CO. (CA) 2007-12-25 — — US disclosed
EP-0832082-B1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ASTRAZENECA AB (SE) 2001-11-21 — — EP disclosed
EP-0749964-B1 N-Heterocyclyl biphenyl sulfonamides ASTRAZENECA AB (SE) 2001-10-04 — — EP disclosed
US-6258817-B1 PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS ZENECA LTD. (GB) 2001-07-10 — — US disclosed
US-6060475-A Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof ZENECA LIMITED (GB) 2000-05-09 — — US disclosed
US-5866568-A ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY ZENECA LIMITED (GB) 1999-02-02 — — US disclosed
CN-1192739-A N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists ZENECA LTD (GB) 1998-09-09 — — CN disclosed
EP-0832082-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1998-04-01 — — EP disclosed
US-5668137-A N-heterocyclic sulfonamides having endothelin receptor activity ZENECA LTD. (GB) 1997-09-16 — — US disclosed
EP-0749964-A1 N-Heterocyclyl biphenyl sulfonamides ZENECA LIMITED (GB) 1996-12-27 — — EP disclosed
WO-1996040681-A1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ZENECA LIMITED (GB) 1996-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME ODC1, AOC1, ADH1C BLM 2757/4885MME 4069/4885LMNA 3145/4885
US-20200283445-A1 DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE TPMT, DPYD, SLC10A1 BLM 2659/4885MME 570/4885LMNA 3744/4885
US-11261190-B2 Dihydropyrimidine compounds and uses thereof in medicine DPYD, TPMT, SLC10A1 BLM 2258/4885MME 550/4885LMNA 3134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.